Physician profile
John A Walker
NPI 1346210994
$845.93
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $17.46 · 2021: $60.74 · 2022: $169 · 2023: $203 · 2024: $13.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.36 | 2019-2023 | Rinvoq, Linzess, Viberzi |
| Intercept Pharmaceuticals, INC. | $98.86 | 2019-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.99 | 2019-2022 | |
| Janssen Biotech, INC. | $59.76 | 2019-2024 | Stelara |
| Braintree Laboratories, INC. | $56.42 | 2019-2023 | Suflave |
| Pfizer INC. | $41.75 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $39.18 | 2023 | Dupixent |
| Genzyme Corporation | $17.69 | 2022 | |
| Boston Scientific Corporation | $17.46 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.29 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.31 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.86 | 2022 | |
| Covidien LP | $15.37 | 2019 | |
| Gilead Sciences, INC. | $12.04 | 2019 | |
| Shire North American Group INC | $11.72 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.